Negative Symptom Interventions in Youth at Risk of Psychosis: A Systematic Review and Network Meta-analysis

Schizophrenia Bulletin

Volumn 44, Issue 4, 2018, Pages 807-823

  Devoe, Daniel J ^a   Peterson, Aaron ^a   Addington, Jean ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

clinical high risk; negative symptoms; network meta analysis; psychosis; schizophrenia; systematic review

Indexed keywords

AMISULPRIDE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; OLANZAPINE; OMEGA 3 FATTY ACID; PEROSPIRONE; RISPERIDONE; ZIPRASIDONE;

ARTICLE; COGNITIVE BEHAVIORAL THERAPY; FAMILY THERAPY; HUMAN; META ANALYSIS; NEGATIVE SYNDROME; NETWORK META-ANALYSIS; OUTCOME ASSESSMENT; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOSIS; QUALITY OF LIFE; RISK FACTOR; SYSTEMATIC REVIEW; TREATMENT DURATION; ADOLESCENT; ADULT; FEMALE; MALE; PATHOPHYSIOLOGY; PSYCHOTHERAPY; SCHIZOPHRENIA; STATISTICS AND NUMERICAL DATA; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; MALE; NETWORK META-ANALYSIS; OUTCOME ASSESSMENT (HEALTH CARE); PSYCHOTHERAPY; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; YOUNG ADULT;

EID: 85048318815     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbx139     Document Type: Article

References (98)

1. McGlashan T, Walsh B, Woods S. The Psychosis-Risk Syndrome: Handbook for Diagnosis and Follow-up. New York, NY: Oxford University Press; 2010.
2. Yung AR, Yuen HP, McGorry PD, et al. Mapping the onset of psychosis: the Comprehensive Assessment of At-Risk Mental States. Aust N Z J Psychiatry. 2005;39:964-971.
3. Fusar-Poli P, Borgwardt S, Bechdolf A, et al. The psychosis high-risk state: a comprehensive state-of-the-art review. JAMA Psychiatry. 2013;70:107-120.
4. Fusar-Poli P, Van Os J. Lost in transition: setting the psychosis threshold in prodromal research. Acta Psychiatr Scand. 2013;127:248-252.
5. Stafford MR, Jackson H, Mayo-Wilson E, Morrison AP, Kendall T. Early interventions to prevent psychosis: systematic review and meta-analysis. BMJ 2013;346:f185.
6. Fusar-Poli P, Borgwardt S. Integrating the negative psychotic symptoms in the high risk criteria for the prediction of psychosis. Med Hypotheses. 2007;69:959-960.
7. Lencz T, Smith CW, Auther A, Correll CU, Cornblatt B. Nonspecific and attenuated negative symptoms in patients at clinical high-risk for schizophrenia. Schizophr Res. 2004;68:37-48.
8. Piskulic D, Addington J, Cadenhead KS, et al. Negative symptoms in individuals at clinical high risk of psychosis. Psychiatry Res. 2012;196:220-224.
9. Kwapil TR, Kwapil TR. Social anhedonia as a predictor of the development of schizophrenia-spectrum disorders. J Abnorm Psychol. 1998;107:558-565.
10. Mason O, Startup M, Halpin S, Schall U, Conrad A, Carr V. Risk factors for transition to first episode psychosis among individuals with ?at-risk mental states'. Schizophr Res. 2004;71:227-237.
11. Yung AR, Phillips LJ, Yuen HP, et al. Psychosis prediction: 12-month follow up of a high-risk (-prodromal') group. Schizophr Res. 2003;60:21-32.
12. Demjaha A, Valmaggia L, Stahl D, Byrne M, McGuire P. Disorganization/cognitive and negative symptom dimensions in the at-risk mental state predict subsequent transition to psychosis. Schizophr Bull. 2012;38:351-359.
13. Devoe D, Cadenhead K, Cannon T, et al. SU127. Negative symptoms in youth at clinical high risk of psychosis. Schizophr Bull. 2017;43(suppl 1):S207-S207.
14. Bechdolf A, Pukrop R, Kohn D, et al. Subjective quality of life in subjects at risk for a first episode of psychosis: a comparison with first episode schizophrenia patients and healthy controls. Schizophr Res. 2005;79:137-143.
15. Nelson B, Yuen HP, Wood SJ, et al. Long-term follow-up of a group at ultra high risk (-prodromal') for psychosis: the PACE 400 study. JAMA Psychiatry. 2013;70:793-802.
16. Dominguez-Martinez T, Kwapil TR, Barrantes-Vidal N. Subjective quality of life in At-Risk Mental State for psychosis patients: relationship with symptom severity and functional impairment. Early Interv Psychiatry. 2015;9:292-299.
17. Wood S, Lin A, Nelson B, McGorry P, Yung A. Negative symptoms in the at-risk mental state-association with transition to psychosis and functional outcome. Early Interv Psychiatry. 2014;8:23.
18. Fusar-Poli P, Papanastasiou E, Stahl D, et al. Treatments of negative symptoms in schizophrenia: meta-analysis of 168 randomized placebo-controlled trials. Schizophr Bull. 2015;41:892-899.
19. Carpenter WT, Schiffman J. Diagnostic concepts in the context of clinical high risk/attenuated psychosis syndrome. Schizophr Bull. 2015;41:1001-1002.
20. Kantrowitz JT, Javitt DC. N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia. Brain Res Bull. 2010;83:108-121.
21. Kantrowitz JT, Woods SW, Petkova E, et al. -D-serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double-blind, placebo-controlled, randomised parallel group mechanistic proof-of-concept trial': correction. Lancet Psychiatry. 2016;3:602.
22. Amminger GP, Schafer MR, Klier CM, et al. Indicated prevention with long-chain omega-3 fatty acids in young people at ultra-high risk for psychosis: a randomized, placebo-controlled trial. Early Interv Psychiatry. 2010;4:7.
23. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of stuDies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700
24. Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162:777-784.
25. Moher D, Shamseer L, Clarke M, et al.; PRISMA-P Group. Preferred reporting items for systematic review and metaanalysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1.
26. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational stuDies in epidemiology: a proposal for reporting. Meta-analysis of Observational StuDies in Epidemiology (MOOSE) group. JAMA. 2000;283:2008-2012.
27. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009;339:b2535.
28. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261-276.
29. Andreasen NC. Scale for the Assessment of Negative Symptoms (SANS). Br J Psychiatry Suppl. 1989;17:173-180
30. Miller TJ, McGlashan TH, Rosen JL, et al. Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. Schizophr Bull. 2003;29:703-715.
31. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Chichester, England: Wiley; 2011.
32. Boyle MA, Samaha AL, Rodewald AM, Hoffmann AN. Evaluation of the reliability and validity of GraphClick as a data extraction program. Comput Human Behav 2013;29:1023-1027.
33. Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised StuDies in Meta-analyses. Ottawa, Canada: Ottawa Hospital Research Institute; 2011.
34. Puhan MA, Schunemann HJ, Murad MH, et al. A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ 2014;349:g5630.
35. Higgins JPT, Green S, Scholten RJPM. Maintaining reviews: updates, amendments and feedback. In: Julian Higgins and Sally Green, eds. Cochrane Handbook for Systematic Reviews of Interventions. Chichester, England: John Wiley Sons, Ltd; 2008:31-49.
36. Woods SW, Walsh BC, Hawkins KA, et al. Glycine treatment of the risk syndrome for psychosis: report of two pilot stuDies. Eur Neuropsychopharmacol. 2013;23:931-940.
37. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry. 1991;148:1301-1308
38. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-188.
39. Collaboration C. Review manager (RevMan) [computer program]: Version; Copenhagen, Denmark: The Nordic Cochrane Centre; 2011.
40. Dunlap WP, Cortina JM, Vaslow JB, Burke MJ. Metaanalysis of Experiments with Matched Groups or Repeated Measures Designs. Washington, DC: American Psychological Association; 1996.
41. Becker LA. Effect Size (ES). Colorado Springs: University of Colorado Colorado Springs; 2000.
42. Dias S, Sutton AJ, Ades AE, Welton NJ. Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Med Decis Making. 2013;33:607-617.
43. Caldwell DM, Ades AE, Higgins JP. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ. 2005;331:897-900.
44. Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in metaanalysis of randomized controlled trials. J Clin Epidemiol. 1997;50:683-691.
45. Cipriani A, Higgins JP, Geddes JR, Salanti G. Conceptual and technical challenges in network meta-analysis. Ann Intern Med. 2013;159:130-137.
46. Salanti G. Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Res Synth Methods. 2012;3:80-97.
47. Jansen JP, Naci H. Is network meta-analysis as valid as standard pairwise meta-analysis. It all depends on the distribution of effect modifiers. BMC Med. 2013;11:159.
48. Cates C. Maintenance treatment for adults with chronic asthma. BMJ 2014;348:g3148.
49. Chaimani A, Higgins JP, Mavridis D, Spyridonos P, Salanti G. Graphical tools for network meta-analysis in STATA. PLoS One. 2013;8:e76654.
50. Dias S, Welton NJ, Sutton AJ, Caldwell DM, Lu G, Ades AE. Evidence synthesis for decision making 4: inconsistency in networks of evidence based on randomized controlled trials. Med Decis Making. 2013;33:641-656.
51. Veroniki AA, Vasiliadis HS, Higgins JP, Salanti G. Evaluation of inconsistency in networks of interventions. Int J Epidemiol. 2013;42:332-345.
52. Song F, Altman DG, Glenny AM, Deeks JJ. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ. 2003;326:472.
53. Cohen J. Statistical Power Analysis for the Behavioral Sciences. Hillsdale, NJ: Lawrence Earlbaum Associates; 1988:20-26.
54. Woods S, Saksa J, Compton M, et al. 112. Effects of ziprasidone versus placebo in patients at clinical high risk for psychosis. Schizophr Bull. 2017;43(suppl 1):S58-S58.
55. Woods SW, Tully EM, Walsh BC, et al. Aripiprazole in the treatment of the psychosis prodrome: an open-label pilot study. Br J Psychiatry Suppl. 2007;51:s96-s101.
56. Piskulic D, Barbato M, Addington J. Effects of cognitive remediation on cognition in young people at clinical high risk of psychosis. Schizophr Res. 2012;136:S245-S246.
57. Miklowitz DJ, O'Brien MP, Schlosser DA, et al. Familyfocused treatment for adolescents and young adults at high risk for psychosis: results of a randomized trial. J Am Acad Child Adolesc Psychiatry. 2014;53:848-858.
58. McGlashan TH, Zipursky RB, Perkins D, et al. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry. 2006;163:790-799.
59. McFarlane WR, Levin B, Travis L, et al. Clinical and functional outcomes after 2 years in the early detection and intervention for the prevention of psychosis multisite effectiveness trial. Schizophr Bull. 2015;41:30-43.
60. Loewy R, Fisher M, Schlosser DA, et al. Intensive auditory cognitive training improves verbal memory in adolescents and young adults at clinical high risk for psychosis. Schizophr Bull. 2016;42(suppl 1):S118-S126.
61. Landa Y, Mueser KT, Wyka KE, et al. Development of a group and family-based cognitive behavioural therapy program for youth at risk for psychosis. Early Interv Psychiatry. 2016;10:511-521.
62. Kantrowitz JT, Woods SW, Petkova E, et al. D-serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double-blind, placebocontrolled, randomised parallel group mechanistic proof-ofconcept trial. Lancet Psychiatry. 2015;2:403-412.
63. Hooker CI, Carol EE, Eisenstein TJ, et al. A pilot study of cognitive training in clinical high risk for psychosis: initial evidence of cognitive benefit. Schizophr Res. 2014;157:314-316.
64. Choi J, Corcoran CM, Fiszdon JM, et al. Pupillometer-based neurofeedback cognitive training to improve processing speed and social functioning in individuals at clinical high risk for psychosis. Psychiatr Rehabil J. 2017;40:33-42.
65. Cadenhead K, Addington J, Cannon T, et al. 23. Omega-3 fatty acid versus placebo in a clinical high-risk sample from the North American Prodrome Longitudinal StuDies (NAPLS) Consortium. Schizophr Bull. 2017;43(suppl 1):S16-S16.
66. Addington J, Epstein I, Liu L, French P, Boydell KM, Zipursky RB. A randomized controlled trial of cognitive behavioral therapy for individuals at clinical high risk of psychosis. Schizophr Res. 2011;125:54-61.
67. Amminger GP, Schafer MR, Papageorgiou K, et al. Longchain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry. 2010;67:146-154.
68. Cannon TD, Huttunen MO, Dahlstrom M, Larmo I, Rasanen P, Juriloo A. Antipsychotic drug treatment in the prodromal phase of schizophrenia. Am J Psychiatry. 2002;159:1230-1232.
69. Fusar-Poli P, Frascarelli M, Valmaggia L, et al. Antidepressant, antipsychotic and psychological interventions in subjects at high clinical risk for psychosis: OASIS 6-year naturalistic study. Psychol Med. 2015;45:1327-1339.
70. Ising HK, Kraan TC, Rietdijk J, et al. Four-year followup of cognitive behavioral therapy in persons at ultra-high risk for developing psychosis: the Dutch Early Detection Intervention Evaluation (EDie-NL) trial. Schizophr Bull. 2016;42:1243-1252.
71. Nordentoft M, Thorup A, Petersen L, et al. Transition rates from schizotypal disorder to psychotic disorder for firstcontact patients included in the OPUS trial. A randomized clinical trial of integrated treatment and standard treatment. Schizophr Res. 2006;83:29-40.
72. Rauchensteiner S, Kawohl W, Ozgurdal S, et al. Testperformance after cognitive training in persons at risk mental state of schizophrenia and patients with schizophrenia. Psychiatry Res. 2011;185:334-339.
73. Ruhrmann S, Bechdolf A, Kuhn KU, et al.; LIPS study group. Acute effects of treatment for prodromal symptoms for people putatively in a late initial prodromal state of psychosis. Br J Psychiatry Suppl. 2007;51:s88-s95.
74. Wessels H, Wagner M, Frommann I, et al. Neuropsychological functioning as a predictor of treatment response to psychoeducational, cognitive behavioral therapy in people at clinical high risk of first episode psychosis. Psychiatr Prax. 2015;42:313-319.
75. Urben S, Pihet S, Jaugey L, Halfon O, Holzer L. A randomized controlled trial of the effectiveness of a computer-assisted cognitive remediation (CACR) program in adolescents with psychosis or at high risk of psychosis: short term and long term outcomes. Early Interv Psychiatry. 2012;6:41.
76. McGorry PD, Yung AR, Phillips LJ, et al. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry. 2002;59:921-928.
77. McGorry PD, Nelson B, Phillips LJ, et al. Randomized controlled trial of interventions for young people at ultra-high risk of psychosis: twelve-month outcome. J Clin Psychiatry. 2013;74:349-356.
78. Berger GE, Wood SJ, Ross M, et al. Neuroprotective effects of low-dose lithium in individuals at ultra-high risk for psychosis. A longitudinal MRI/MRS study. Curr Pharm Des. 2012;18:570-575.
79. McGorry PD, Nelson B, Markulev C, et al. Effect of 2-3 polyunsaturated fatty acids in young people at ultrahigh risk for psychotic disorders: the NEURAPRO randomized clinical trial. JAMA Psychiatry. 2017;74:19-27.
80. Kobayashi H, Morita K, Takeshi K, et al. Effects of aripiprazole on insight and subjective experience in individuals with an at-risk mental state. J Clin Psychopharmacol. 2009;29:421-425.
81. Liu CC, Chien YL, Hsieh MH, Hwang TJ, Hwu HG, Liu CM. Aripiprazole for drug-naive or antipsychotic-short-exposure subjects at putatively prodromal or early state of psychosis: an open-label study. Early Interv Psychiatry. 2012;6:101.
82. Washida K, Takeda T, Habara T, Sato S, Oka T, Tanaka M, Yoshimura Y, Aoki S. Efficacy of second-generation antipsychotics in patients at ultra-high risk and those with firstepisode or multi-episode schizophrenia. Neuropsychiatr Dis Treat. 2013;9:861-868.
83. Tsujino N, Nemoto T, Morita K, Katagiri N, Ito S, Mizuno M. Long-term efficacy and tolerability of perospirone for young help-seeking people at clinical high risk: a preliminary open trial. Clin Psychopharmacol Neurosci. 2013;11:132-136.
84. Von Hippel PT. The heterogeneity statistic I(2) can be biased in small meta-analyses. BMC Med Res Methodol. 2015;15:35
85. Kumar S, Chaudhury S. Efficacy of amisulpride and olanzapine for negative symptoms and cognitive impairments: an open-label clinical study. Ind Psychiatry J. 2014;23:27-35.
86. Danion J-M, Rein W, Fleurot O; the Amisulpride Study Group. Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Am J Psychiatry. 1999;156:610-616.
87. Kim JS, Kornhuber HH, Schmid-Burgk W, Holzmuller B. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci Lett. 1980;20:379-382.
88. Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Silipo G, Lichtenstein M. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry. 1999;56:29-36.
89. Leon AC, Davis LL, Kraemer HC. The role and interpretation of pilot stuDies in clinical research. J Psychiatr Res. 2011;45:626-629.
90. Miyake N, Miyamoto S, Yamashita Y, Ninomiya Y, Tenjin T, Yamaguchi N. Effects of N-acetylcysteine on cognitive functions in subjects with an at-risk mental state: a case series. J Clin Psychopharmacol. 2016;36:87-88.
91. Sommer IE, Bearden CE, Van Dellen E, et al. Early interventions in risk groups for schizophrenia: what are we waiting for. NPJ Schizophr. 2016;2:16003.
92. Marder SR, Daniel DG, Alphs L, Awad AG, Keefe RS. Methodological issues in negative symptom trials. Schizophr Bull. 2011;37:250-254.
93. Kirkpatrick B, Fenton WS, Carpenter WT Jr, Marder SR. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull. 2006;32:214-219.
94. Pelletier-Baldelli A, Strauss GP, Visser KH, Mittal VA. Initial development and preliminary psychometric properties of the Prodromal Inventory of Negative Symptoms (PINS). Schizophr Res. doi:10.1016/j.schres.2017.01.055. [Epub ahead of print]
95. Corcoran CM, Kimhy D, Parrilla-Escobar MA, et al. The relationship of social function to depressive and negative symptoms in individuals at clinical high risk for psychosis. Psychol Med. 2011;41:251-261.
96. Dong C, Hashimoto K. Early intervention for psychosis with N-methyl-d-aspartate receptor modulators. Clin Psychopharmacol Neurosci. 2015;13:328-329.
97. Woods SW, Kantrowitz JT, Javitt DC. NMDAR-based treatments for patients at clinical high risk for psychosis. Biol Psychiatry. 2014;1:11S.
98. Yung AR, Woods SW, Ruhrmann S, et al. Whither the attenuated psychosis syndrome. Schizophr Bull. 2012;38: 1130-1134.